Loading…
← CockpitCompetitor Analysis › BWAY Brainsway Ltd Sponsored ADROpen in the cockpit ↗

Brainsway Ltd Sponsored ADRBWAYCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum laggard 11
Mkt cap
$373M
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$1.45M
20-day average traded
Fwd P/E
20.3×
forward earnings
ROIC−WACC
+15.7 pp
WACC 11.8%
Hurdle
+6 pp
Req g minus delivered
Next earnings
119 days
17 Mar 2027
Close · USD$8.98
1D-1.4%
1W-20.1%
1M-25.4%
3M-40.0%
6M-41.2%
YTD-5.6%
1Y+18.3%
ATR %7.7%
Beta1.59
52w lowhigh48.4% off high

What Brainsway Ltd Sponsored ADR does

Employees: 129

Brainsway Ltd Sponsored ADR at a glance

Size Brainsway Ltd Sponsored ADR (BWAY) is a United States Health Care company (Medical Specialties) with a market value of $373M, the 2898th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.98 on 18 Nov 2026.

Performance Over six months the shares fell 41.2%, against -15.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 32.5% over the last twelve months (peer median +7.1%); the operating margin is 13.6% (peer median 7.9%).

Valuation It trades at 20.3× forward earnings against a peer median of 15.8× (4th most expensive of 11).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 15.7 points above its cost of capital (11.8% WACC).

Short interest Short interest is 0.5% of the free float (30 Oct 2026).

Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 85BWAY 60
Six months, rebased to 100: Brainsway Ltd Sponsored ADR against the median of its 20 peers (local-currency closes).

Brainsway Ltd Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$65.5M$52.6M$41.2M$31.7M$27.1M
Revenue growth—+28%+30%+17%—
Gross profit$49.8M$39.0M$30.1M$23.0M$20.4M
EBITDA$10.7M$5.91M$3.18M-$3.58M-$10.3M
Net income$10.1M$7.64M$2.93M-$4.19M-$13.3M
Free cash flow$12.9M$15.3M$6.53M-$1.10Mn/a
Capital expenditure-$517,592$3.02M$4.79M$2.40M$20,918
Total debt$6.88M$6.82M$5.62M$471,003$488,006

Quarterly statements and history in the cockpit →

Brainsway Ltd Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-40%-20%0%+20%3005626748605186CV041830SBS16096883384736458870MASS300238EMBCBWAY6-month return →1-month return →
Up and to the right = strong over both horizons. Brainsway Ltd Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%10×20×30×300562605186041830SBS6883383006534588706929EMBC688133BWAYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Brainsway Ltd Sponsored ADR is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%30056220410418301609688338458870MASSBWAYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Brainsway Ltd Sponsored ADR is the large dot.

Brainsway Ltd Sponsored ADR competitors and peer comparison

How Brainsway Ltd Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Brainsway Ltd Sponsored ADR against its 20 peers (data as of 18 Nov 2026)
MeasureBWAYPeer medianRank in peer set
1-month return-25.4%-10.9%2nd lowest of 21
6-month return-41.2%-15.0%3rd lowest of 20
Distance from 52-week high-48.4%-43.6%5th lowest of 21
Revenue growth (TTM)+32.5%+7.1%3rd highest of 21
Operating margin13.6%7.9%10th highest of 21
Forward P/E20.3×15.8×4th most expensive of 11
Growth the price implies (Req g, 7 yrs)24.9%-6.3%2nd most demanding of 14
Growth delivered (Del g)+18.8%+4.4%3rd highest of 14
Hurdle (Req g minus delivered)+6.1 pp-2.9 pp4th most demanding of 14
ROIC minus cost of capital+15.7 pp+4.7 pp5th highest of 20
EV / EBITDA29.6×7.9×2nd most expensive of 11
Net debt / EBITDA-5.3×-1.2×3rd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%20.3×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%25.3×-4.2%-6.0%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%n/an/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%n/a17.1%+18.1%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%37.2×n/an/a
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
InBody 041830.KSSouth Korea$380M-13%+22%22%11.3×-10.3%+16.9%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Taidoc Technology 4736.TWTaiwan$387M0%0%19%n/a-9.5%-6.6%
Shanghai Kehua Bio-Engineering 002022.SZChina$389M-14%+7%-40%n/an/an/a
Cerus CERSUnited States$392M-28%+14%-12%n/an/an/a
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
SEERS 458870.KSSouth Korea$392M-70%+174%37%15.2×-6.3%+247.0%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
908 Devices MASSUnited States$396M+36%+14%-33%n/a41.7%+15.9%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%8.4×n/an/a

Questions

Which companies are Brainsway Ltd Sponsored ADR's closest peers?
The cockpit's peer set: Guangdong Transtek Medical Electronics (300562.SZ), ACRO Biomedical (6748.TWO), Medcaptain Medical Technology (2041.HK), Shanghai General Healthy Information & Technology (605186.SS), CapsoVision (CV), InBody (041830.KS), Stratec (SBS.DE), Star Sports Medicine (1609.HK).
Is Brainsway Ltd Sponsored ADR expensive compared with its peers?
On forward p/e it trades at 20.3× against a peer median of 15.8×, 4th most expensive of 11 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Brainsway Ltd Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned -41.2% against -15.0% for the median peer; over one year +18.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.